Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $296.9 million as the latest value for Q4 2023.

  • Quarterly Preferred Stock Liabilities changed N/A to $296.9 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $296.9 million through Dec 2023, changed N/A year-over-year, with the annual reading at $296.9 million for FY2023, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2023 was $296.9 million at Cartesian Therapeutics, up from $5.0 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $296.9 million in Q4 2023, with the low at $296.9 million in Q4 2023.